Celldex Therapeutics vs Cytomed Therapeutics
Celldex Therapeutics is the larger business, with $1.5m of revenue in fiscal 2025 against $248,384 for Cytomed Therapeutics (6.2 times as much). Cytomed Therapeutics grew faster (377.5% against -78.0%). Cytomed Therapeutics kept more of each dollar of sales as profit: a net margin of -1227.1% against -16748.0%. Celldex Therapeutics carries less debt relative to equity (0.0% against 6.3%).
| Latest fiscal year | Celldex TherapeuticsCLDX, 2025 | Cytomed TherapeuticsGDTC, 2025 |
|---|---|---|
| Revenue | $1.5m | $248,384 |
| Revenue growth | -78.0% | 377.5% |
| Net income | −$259m | −$3.0m |
| Operating margin | -18599.8% | — |
| Net margin | -16748.0% | -1227.1% |
| Return on equity | -40.6% | -52.3% |
| Free cash flow | −$214m | −$3.3m |
| Cash | $28.9m | $1.6m |
| Total debt | $0 | $318,456 |
| Debt to equity | 0.0% | 6.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 198 | — |
| Market value | $2.32bn | $10.2m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 0 buys, 2 sales | 5 buys, 0 sales |